blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3524230

EP3524230 - PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.06.2022
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  09.07.2021
FormerGrant of patent is intended
Status updated on  10.03.2021
FormerRequest for examination was made
Status updated on  21.02.2020
FormerThe application has been published
Status updated on  12.07.2019
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Alkahest, Inc.
125 Shoreway Road, Suite D
San Carlos, CA 94070 / US
[2019/33]
Inventor(s)01 / FETSCHER, Alfred
Boehringer Ingelheim GmbH, Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
02 / SCHER, Jochen Matthias
Boehringer Ingelheim GmbH, Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
 [2019/33]
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2019/33]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Application number, filing date18213458.502.04.2013
[2019/33]
Priority number, dateEP2012016307804.04.2012         Original published format: EP 12163078
[2019/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3524230
Date:14.08.2019
Language:EN
[2019/33]
Type: B1 Patent specification 
No.:EP3524230
Date:11.08.2021
Language:EN
[2021/32]
Search report(s)(Supplementary) European search report - dispatched on:EP10.07.2019
ClassificationIPC:A61K9/00, A61K9/20, A61K9/28, A61K9/48, A61K31/4545, A61K9/16, A61P1/04, A61P17/00
[2021/07]
CPC:
A61K31/4545 (EP,KR,US); A61K9/2054 (EP,KR,US); A61K9/0053 (EP,US);
A61K9/1617 (EP,US); A61K9/2009 (KR); A61K9/2013 (EP,KR,US);
A61K9/2018 (EP,KR,US); A61K9/2027 (EP,KR,US); A61K9/2031 (EP,KR,US);
A61K9/2059 (KR); A61K9/2077 (EP,US); A61K9/2813 (KR,US);
A61K9/284 (EP,KR,US); A61K9/2853 (US); A61K9/2866 (EP,KR,US);
A61K9/4858 (KR,US); A61K9/4866 (KR,US); A61P1/04 (EP);
A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (KR);
A61P13/12 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P21/04 (EP);
A61P27/02 (EP); A61P29/00 (EP,KR); A61P31/00 (EP,KR);
A61P35/00 (EP); A61P37/00 (EP,KR); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP,KR); A61P43/00 (EP);
A61P7/06 (EP); A61P9/00 (EP) (-)
Former IPC [2019/33]A61K9/00, A61K9/20, A61K9/28, A61K9/48, A61K31/4545, A61P29/00, A61K9/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/13]
Former [2019/33]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:PHARMAZEUTISCHE FORMULIERUNGEN MIT CCR3-ANTAGONISTEN[2019/33]
English:PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS[2019/33]
French:FORMULATIONS PHARMACEUTIQUES COMPRENANT DES ANTAGONISTES DE CCR3[2019/33]
Examination procedure13.02.2020Amendment by applicant (claims and/or description)
13.02.2020Examination requested  [2020/13]
13.02.2020Date on which the examining division has become responsible
11.03.2021Communication of intention to grant the patent
01.07.2021Fee for grant paid
01.07.2021Fee for publishing/printing paid
01.07.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13714618.9  / EP2833864
Divisional application(s)EP21190323.2  / EP3970693
Opposition(s)12.05.2022No opposition filed within time limit [2022/29]
Fees paidRenewal fee
25.03.2019Renewal fee patent year 03
25.03.2019Renewal fee patent year 04
25.03.2019Renewal fee patent year 05
25.03.2019Renewal fee patent year 06
25.03.2019Renewal fee patent year 07
16.03.2020Renewal fee patent year 08
26.04.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL11.08.2021
CY11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
MC11.08.2021
MK11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
TR11.08.2021
BG11.11.2021
GR12.11.2021
LU02.04.2022
[2024/29]
Former [2024/23]AL11.08.2021
CY11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
MC11.08.2021
MK11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
LU02.04.2022
Former [2024/20]AL11.08.2021
CY11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
MC11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
LU02.04.2022
Former [2023/08]AL11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
MC11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
LU02.04.2022
Former [2023/06]AL11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
MC11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/36]AL11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
RO11.08.2021
RS11.08.2021
SI11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/29]AL11.08.2021
CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
RO11.08.2021
RS11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/25]CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
RO11.08.2021
RS11.08.2021
SK11.08.2021
SM11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/24]CZ11.08.2021
EE11.08.2021
HR11.08.2021
LT11.08.2021
LV11.08.2021
RO11.08.2021
RS11.08.2021
SK11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/10]HR11.08.2021
LT11.08.2021
LV11.08.2021
RS11.08.2021
BG11.11.2021
GR12.11.2021
Former [2022/09]LT11.08.2021
RS11.08.2021
BG11.11.2021
Former [2022/08]LT11.08.2021
BG11.11.2021
Documents cited:Search[XDI]WO2010115836  (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-7,11,14 * examples 135, 142, 150 * * page 127, line 38 - page 128, line 41 * * page 46, line 13 - line 45 * * page 132; example B * * page 125 - lines 2, 4-5 * * page 126, lines 6, 8 * [I] 1-15;
 [XPI]WO2012045803  (BOEHRINGER INGELHEIM INT [DE], et al) [XP] 1-7,11,14 * page 11, lines 6-21 * * page 50, lines 1-4 * * page 53, line 31 * * page 54, lines 1-2 * * pages 61-62; example B) * * claim - *[I] 1-15;
 [Y]  - GERBER B O ET AL, "Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils", CURRENT BIO, CURRENT SCIENCE, GB, (19971101), vol. 7, no. 11, doi:10.1016/S0960-9822(06)00371-X, ISSN 0960-9822, pages 836 - 843, XP004671726 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/S0960-9822(06)00371-X
 [Y]  - AMERIO PAOLO ET AL, "Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications", CURRENT DRUG TARGETS. INFLAMMATION AND ALL, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (20030301), vol. 2, no. 1, ISSN 1568-010X, pages 81 - 94, XP009139038 [Y] 1-15 * abstract * * page 7/17, paragraph "Atopic dermatitis" - page 8/17 *
 [Y]  - LIANNE I. WILLEMS ET AL, "Small molecule antagonists for chemokine CCR3 receptors", MEDICINAL RESEARCH REVIEWS, US, (20090101), doi:10.1002/med.20181, ISSN 0198-6325, pages n/a - n/a, XP055598161 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1002/med.20181
by applicantWO2010115836
    - LUSTER, New Eng. J Med., (19980000), vol. 338, pages 436 - 445
    - ROLLINS, Blood, (19970000), vol. 90, pages 909 - 928
    - LLOYD, Curr. Opin. Pharmacol., (20030000), vol. 3, pages 443 - 448
    - MURRAY, Current Drug Targets, (20060000), vol. 7, pages 579 - 588
    - SMIT, Eur J Pharmacol, (20060000), vol. 533, pages 277 - 88
    - HORUK, Trends Pharm. Sci., (19940000), vol. 15, pages 159 - 165
    - MURPHY, Pharmacol Rev., (20020000), vol. 54, no. 2, pages 227 - 229
    - ALLEN, Annu. Rev. Immunol., (20070000), vol. 25, pages 787 - 820
    - BEN-BARRUCH et al., Cell, (19930000), vol. 72, pages 415 - 425
    - LUSTER, New Eng. J. Med., (19980000), vol. 338, pages 436 - 445
    - CHARO et al., Proc. Natl. Acad. Sci. USA, (19940000), vol. 91, pages 2752 - 2756
    - COMBADIERE et al., J. Biol. Chem., (19950000), vol. 270, pages 16491 - 16494
    - POWER et al., J. Biol. Chem., (19950000), vol. 270, pages 19495 - 19500
    - SANSON et al., Biochemistry, (19960000), vol. 35, pages 3362 - 3367
    - BABA et al., J. Biol. Chem., (19970000), vol. 272, pages 14893 - 14898
    - YOSHIE et al., J. Leukoc. Biol., (19970000), vol. 62, pages 634 - 644
    - NAPOLITANO et al., J. Immunol., (19960000), vol. 157, pages 2759 - 2763
    - BERNARDINI et al., Eur. J. Immunol., (19980000), vol. 28, pages 582 - 588
    - BONINI et al., DNA and Cell Biol., (19970000), vol. 16, pages 1249 - 1256
    - SCHWEICKART et al., J Biol Chem, (20000000), vol. 275, pages 9550 - 9556
    - WELLS; SCHWARTZ, Curr. Opin. Biotech., (19970000), vol. 8, pages 741 - 748
    - COMERFORD, Bioessays., (20070000), vol. 29, no. 3, pages 237 - 47
    - WEGMANN, Am J Respir Cell Mol Biol., (20070000), vol. 36, no. l, pages 61 - 67
    - FRYER, J Clin Invest., (20060000), vol. 116, no. 1, pages 228 - 236
    - DE LUCCA, Curr Opin Drug Discov Devel., (20060000), vol. 9, no. 4, pages 516 - 524
    - WATSON PS, Bioorg Med Chem Lett., (20060000), vol. 16, no. 21, pages 5695 - 5699
    - DE LUCCA, J Med Chem., (20050000), vol. 48, no. 6, pages 2194 - 2211
    - LIST et al., Arzneiformen-lehre, Wissenschaftliche Verlagsgesellschaft mbH, page 70ff
    - VOIGT R., Lehrbuch der pharmazeutischen Technologie [Textbook of Pharmaceutical Technology, Verlag Chemie, page 148
    - TAKEDA et al., Nature, (20090000), vol. 460, no. 7252, pages 225 - 30
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.